CSCC Lesions Found in Few Patients Treated With PD-1/PD-L1 Checkpoint Inhibition
November 13th 2018An analysis of patients who presented to MD Anderson Cancer Center’s dermatology clinic following treatment with anti–PD-1/PD-L1 treatment suggests a potential association between the development of cutaneous squamous cell carcinoma lesions and PD-1/PD-L1 checkpoint inhibition.
Read More
Two Rapid-Fire Abstracts Break Down Biomarkers of Response and Resistance
November 12th 2018An analysis of immunologic biomarkers in a phase II trial of patients with advanced colorectal cancer treated with chemotherapy and PD-1 checkpoint inhibition identified several factors associated with a patient’s beneficial response to the chemo-immunotherapy regimen, according to findings presented during the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Combination Therapy With Mogamulizumab Demonstrates Tolerable and Manageable AEs
November 12th 2018Results from a two-part, phase I dose-escalation and -expansion trial involving mogamulizumab in combination with durvalumab or tremelimumab for the treatment of patients with advanced solid tumors demonstrated mild-to-moderate adverse events that were tolerable and manageable, according to Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, during his presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Phase I Study Considers Potential for Personalized Immunotherapy in Glioblastoma
November 11th 2018A peptide-based personalized vaccine demonstrated encouraging signals of efficacy and was well tolerated in patients with newly diagnosed glioblastoma, according to the results of the phase I GAPVAC-101 trial.
Read More
CD8-Tracer Is Safe, Shows Biodistribution of T Cells in Tumors
November 10th 2018The CD8-tracer 89Zr-IAB22M2C, an anti-CD8 radiolabeled minibody, was found to be safe, well-tolerated, and demonstrated whole-body biodistribution of CD8-positive T cells in tumors and reference tissues, according to first-in-human results presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Computer Analysis Determines Best Practices for Use of Tumor Mutational Burden in Patient Care
November 10th 2018In an effort to determine best practices and ensure consistent clinical interpretation of tumor mutational burden assessment for patients with cancer, a group of diagnostic test partners conducted an in silico analysis and found that panel-derived TMB strongly correlated with whole-exome sequencing data provided from The Cancer Genome Atlas.
Read More
Tawbi Highlights Adjuvant Options for Patients With Melanoma
November 10th 2018There has been a rapid expansion to the treatment landscape for adjuvant melanoma and there is no head-to-head comparative data for the challenge of selecting between immunotherapy and targeted therapy. When selecting a type of therapy, communicating relative merits and risks of both options to patients is necessary in making a shared decision, said Hussein Tawbi, MD, PhD.
Read More
Advanced CSCC Landscape Appears Promising After PD-1 Inhibitor Approval
November 9th 2018According to Anna C. Pavlick, BSM, MS, DO, MBA, the treatment landscape for cutaneous squamous cell carcinoma has changed dramatically in September 2018. During her session at the <em>36th Annual</em> CFS<sup>®</sup>, she said this is due to PD-1 inhibitor cemiplimab, the first agent approved specifically for advanced CSCC.
Read More
Personalized Immunotherapy Regimens Hinge on the Discovery of Effective Biomarkers, Expert Says
November 9th 2018Personalized immunotherapy regimens for patients with cancer is a long-term goal of the immuno-oncology field, yet progress toward this goal necessitates the discovery of an effective biomarker for guiding treatment decision making, according to Jason Luke, MD.
Read More
Immunotherapy/TKI Combinations in Advanced RCC
November 8th 2018Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.
Watch
New CLL Survival Milestones Reached
November 8th 2018Richard Furman, MD, discusses how survival times for patients with chronic lymphocytic leukemia have increased dramatically in the past decade, thanks to an ever-expanding armamentarium of novel agents and more patients now being diagnosed earlier.
Read More
CAR T cells Making a Splash in DLBCL
November 8th 2018The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year, explained Anas Younes, MD, during a presentation at the <em>36th Annual </em>CFS.
Read More
Molecular Characterization Plays Vital Role in Selecting Optimal Colon Cancer Treatment
November 2nd 2018Al B. Benson III, MD, FACP, FASCO, discusses the treatment landscape for advanced and metastatic CRC and how molecular profiling can play a vital role in selecting the optimal treatment plan for each patient. He also emphasizes the importance of participation in clinical trials to further understand these patients.
Read More
Etiology of HCC Plays a Critical Role in Treatment Choice as Landscape Grows, Says Mody
November 2nd 2018Kabir Mody, MD, discusses the evolution of the hepatocellular carcinoma treatment landscape over the past year during a presentation at the 2018 International Society of Gastrointestinal Oncology.
Read More
Ochsner's Precision Cancer Therapies Program Brings Early Phase Trials to the Community Setting
November 1st 2018During a presentation at the Association of Community Cancer Centers’ 35th National Oncology Conference, Marc Matrana, MD, discussed the development of the Ochsner Health System’s Precision Cancer Therapies Program to provide early phase clinical trials in the community setting across the state.<br />
Read More
Expert Panel Discusses the Financial and Economic Impact of Biosimilars
November 1st 2018During a preconference presentation at the Association of Community Cancer Centers 35th National Oncology Conference in Phoenix, a panel of experts discussed the challenges they foresee with the wave of new biosimilar launches expected in 2019.
Read More
The Key to Becoming a More Resilient Member of the Oncology Team
October 30th 2018In a presentation during the Association of Community Cancer Centers 35th National Oncology Conference (NOC) in Phoenix, Arizona, featured speaker Vicki Hess, RN, MS, discussed how oncology teams can become more resilient in the face of challenges.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch